Coya Posts Wider-Than-Expected Q3 Loss, Revenue Down 93%, Going-Concern Warning
COYA sits 20% above its 52-week low of $2.72.
Summary
Coya reported a Q3 adjusted loss of 45 cents a share, worse than the 34-cent consensus and the prior year's 13-cent loss. Revenue fell 93.4% to $234 thousand, though that still topped the $85.71 thousand analysts expected. The quarter's net loss was $10.62 million, driven by higher ALS trial spending. The 10-Q filed this morning carries an explicit going-concern warning: $35.8 million of cash against an $86.4 million accumulated deficit. Shares are down 33.5% this quarter and 42.6% year to date, and the ALSTARS ALS readout in early 2027 is the binary event that decides whether the current cash balance is enough.
At the time of this announcement, COYA was trading at $3.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $78.1M. The 52-week trading range was $2.72 to $6.62. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.